Cargando…
Cost-effectiveness of adalimumab for early-stage Dupuytren’s disease: an economic evaluation based on a randomized controlled trial and individual-patient simulation model
AIMS: To estimate the potential cost-effectiveness of adalimumab compared with standard care alone for the treatment of early-stage Dupuytren’s disease (DD) and the value of further research from an NHS perspective. METHODS: We used data from the Repurposing anti-TNF for Dupuytren’s disease (RIDD) r...
Autores principales: | Dakin, Helen, Rombach, Ines, Dritsaki, Melina, Gray, Alastair, Ball, Catherine, Lamb, Sarah E., Nanchahal, Jagdeep |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The British Editorial Society of Bone & Joint Surgery
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9709491/ https://www.ncbi.nlm.nih.gov/pubmed/36378072 http://dx.doi.org/10.1302/2633-1462.311.BJO-2022-0103.R2 |
Ejemplares similares
-
Dupuytren’s disease: where do we stand?
por: Grazina, Rita, et al.
Publicado: (2019) -
Expression of VEGF, its receptors, and HIF-1α in Dupuytren’s disease
por: Holzer, Lukas A, et al.
Publicado: (2013) -
Adiponectin inhibits fibrosis of the palmar aponeurosis in Dupuytren’s contracture in male patients
por: Yamanaka, Yoshiaki, et al.
Publicado: (2023) -
What do we know about managing Dupuytren’s disease cost-effectively?
por: Dritsaki, Melina, et al.
Publicado: (2018) -
Percutaneous fixation with Kirschner wires versus volar locking-plate fixation in adults with dorsally displaced fracture of distal radius: five-year follow-up of a randomized controlled trial
por: Costa, M. L., et al.
Publicado: (2019)